J J Gagne

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Epidemiology 23:238-46. 2012
  2. pmc Health advisories and patterns of patient monitoring among new users of antidepressant medications
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Suite 3030, 1620 Tremont St, Boston, MA 02120, USA
    J Clin Psychopharmacol 29:590-4. 2009
  3. doi request reprint Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA
    Drug Saf 37:151-61. 2014
  4. doi request reprint Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA Electronic address
    Value Health 16:1054-62. 2013
  5. doi request reprint Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system
    J J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 92:80-6. 2012
  6. pmc An event-based approach for comparing the performance of methods for prospective medical product monitoring
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:631-9. 2012
  7. doi request reprint Design considerations in an active medical product safety monitoring system
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Pharmacoepidemiol Drug Saf 21:32-40. 2012
  8. doi request reprint Antidepressants and fracture risk in older adults: a comparative safety analysis
    J J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 89:880-7. 2011
  9. pmc A combined comorbidity score predicted mortality in elderly patients better than existing scores
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 64:749-59. 2011
  10. pmc Refilling and switching of antiepileptic drugs and seizure-related events
    J J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 88:347-53. 2010

Detail Information

Publications15

  1. pmc Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Epidemiology 23:238-46. 2012
    ..These systems will rely on algorithms to generate alerts about potential safety concerns...
  2. pmc Health advisories and patterns of patient monitoring among new users of antidepressant medications
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Suite 3030, 1620 Tremont St, Boston, MA 02120, USA
    J Clin Psychopharmacol 29:590-4. 2009
    ..We sought to identify patterns of patient monitoring after antidepressant initiation in British Columbia before and after issuance of health advisories...
  3. doi request reprint Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA
    Drug Saf 37:151-61. 2014
    ..Methods for near-real-time monitoring of new drugs in electronic healthcare data are needed...
  4. doi request reprint Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA Electronic address
    Value Health 16:1054-62. 2013
    ..Clinicians and payers require rapid comparative effectiveness (CE) evidence generation to inform decisions for new drugs. We empirically assessed treatment dynamics of newly marked drugs and their implications for conducting CE research...
  5. doi request reprint Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system
    J J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 92:80-6. 2012
    ..3 cases per 1,000 person-years (95% CI: -0.5, 1.0). In a setting in which false positivity is a major concern, the system did not generate alerts for the three drug-outcome pairs...
  6. pmc An event-based approach for comparing the performance of methods for prospective medical product monitoring
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:631-9. 2012
    ..Little attention has been given to how to compare methods in this setting...
  7. doi request reprint Design considerations in an active medical product safety monitoring system
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Pharmacoepidemiol Drug Saf 21:32-40. 2012
    ..The cohort approach generally is preferred in other situations and particularly when timing of exposure or outcome is uncertain because cohort approaches are less vulnerable to biases resulting from misclassification...
  8. doi request reprint Antidepressants and fracture risk in older adults: a comparative safety analysis
    J J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 89:880-7. 2011
    ..Although SSRI use was associated with the highest rate of fractures, variation in fracture risk across specific antidepressant medications did not depend on affinity for serotonin transport receptors...
  9. pmc A combined comorbidity score predicted mortality in elderly patients better than existing scores
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 64:749-59. 2011
    ..To develop and validate a single numerical comorbidity score for predicting short- and long-term mortality, by combining conditions in the Charlson and Elixhauser measures...
  10. pmc Refilling and switching of antiepileptic drugs and seizure-related events
    J J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 88:347-53. 2010
    ..19 (95% CI 0.35-3.99). Refilling the same AED prescription was associated with an elevated risk of seizure-related events whether or not the refill involved switching from a brand-name to a generic product...
  11. pmc Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis
    Joshua J Gagne
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Neurology 74:995-1002. 2010
    ..We tested the hypothesis that anti-inflammatory drugs reduce PD incidence and that there are differential effects by type of anti-inflammatory, duration of use, or intensity of use...
  12. doi request reprint Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies
    Joshua J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    Pharmacoepidemiol Drug Saf 18:259-68. 2009
    ..A meta-analysis was conducted to summarize results and explain variation of published epidemiologic studies on risks of renal dysfunction and death associated with aprotinin...
  13. pmc Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis
    Aaron S Kesselheim
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Drugs 70:605-21. 2010
    ..In the absence of better data, physicians may want to consider more intensive monitoring of high-risk patients taking AEDs when any switch occurs...
  14. doi request reprint Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development
    S Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 90:777-90. 2011
    ....
  15. pmc Confounder summary scores when comparing the effects of multiple drug exposures
    Suzanne M Cadarette
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 19:2-9. 2010
    ..We compared three analytic strategies to control for confounding based on measured variables: conventional multivariable, exposure propensity score (EPS), and disease risk score (DRS)...